**ADVANTAGE:**
Drug loading throughout the entire spherical volume

Consistent loading throughout the sphere offers potential for optimal drug loading and delivery.

Cross section of HepaSphere Microspheres loaded with doxorubicin originally taken at 20x magnification. The red color indicates the presence of doxorubicin. Data on file at BioSphere Medical.

**ADVANTAGE:**
Low systemic drug exposure of doxorubicin

Plasma concentration of doxorubicin and doxorubicinol of HepaSphere loaded microspheres in a VX-2 model.

**ADVANTAGE:**
Effective tumor cell “kill” rate vs. bland embolization

**ADVANTAGE:**
Penetration of doxorubicin into surrounding tissue

In a VX-2 animal model, HepaSphere 50-100μm Microspheres eluted doxorubicin to a distance of up to 1600 microns into the surrounding tumor tissue assessed 24 hours after delivery.

**ADVANTAGE:**
Sustains greater tumoral concentration of doxorubicin within tumor vs. outside of tumor

Intra-tumoral/peri-tumoral concentration of doxorubicin loaded HepaSphere Microspheres in a VX-2 model.

**ADVANTAGE:**
Encouraging initial clinical experience with HepaSphere Microspheres in HCC Patients

**RESULTS**

6 MONTHS FOLLOW-UP

<table>
<thead>
<tr>
<th>50 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>31 patients</td>
</tr>
</tbody>
</table>

- 50, Child-Pugh A/B
- Loading: 50 mg
- # treatments: Up to 3
- Follow-up Interval: 6 months
- Objective Response: 77.4%

Note: Not controlled, not randomized, 4 sites, doxorubicin or epirubicin

---

